Revvity Diprenorphine -, 250µci (9.25mbq)

Revvity 250µCi quantity of Diprenorphine [15,16-³H]-, is available for your research. Diprenorphine acts as an antagonist at the μ-opioid receptor (MOR), κ-opioid (KOR), and δ-opioid receptor (DOR) and is used to reverse the effects of potent opioid analgesics in veterinary medicine. The opioid receptors are a group of GPCRs that are potential drug targets for pain, depression, and drug abuse. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET1121: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Floettmann E, Bui K, Sostek M, Payza K, Eldon M. (2017), Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation. J Pharmacol Exp Ther, 361(2): 280-291.Marino, S. F. (2009), High-level production and characterization of a g-protein coupled receptor signaling complex. FEBS Journal, 276: 4515–4528.